泽菲与多西他赛维持治疗晚期非小细胞肺癌

Treatment of gemzar or taxotere maintenance therapy on advanced non-small cell lung cancer

目的探讨不同维持治疗方案对晚期非小细胞肺癌的临床疗效。方法选择ⅢB～Ⅳ期非小细胞肺癌,经4周期标准泽菲、顺铂化疗方案治疗病情未进展的患者60例,将其随机分为A、B、C 3组,A组给予泽菲与对症支持治疗;B组给予多西他赛与对症支持治疗;C组仅给予对症支持治疗。以中位无进展生存时间(PFS)作为观察终点,比较泽菲与多西他赛维持治疗晚期非小细胞肺癌的疗效、不良反应及生存期。结果 A、B、C 3组PFS分别为5.9、6.2和2.8个月,3组患者中位PFS比较,差异有统计学意义(P<0.05)。A组与B组不良反应发生率比较差异无统计学意义(P>0.05)。结论泽菲与多西他赛维持治疗晚期非小细胞肺癌安全有效,能延长患者的PFS,且不良反应轻。

Objective To evaluate the clinical efficacy, toxicity and the median progression-free survival （PFS） of gemzar or taxotere in maintenance therapy of advanced non-small cell iung cancer （NSCLC）. Methods 60 patients diagnosed with advanced non-smalI cell lung cancer were enrolled in this study. After 4 courses of standard gemzar and cisplatin chemotherapy,the treatment conditions of 60 patients did not progress, and then they were randomly divided into group A, B and C. group A were given Gemzar and support treatment, group B given Taxotere and support treatment, group C given only support treatment. Taking median PFS as end point. Results PFSs of groups A, B,C were 5.9,6.2, 2.8 months,respectively,there was significant difference in median PFS （P〈0.05）. There was no significant difference in side effect occurrence between group A and group B （P〉0.05）. Conclusion It is safe and effective to treat advanced NSCLC with gemzar or taxotere.